Videos

At the 2022 San Antonio Breast Cancer Symposium, Virgina Kaklamani, MD, discusses the impact of the duration of CDK4/6 inhibitor treatment on the efficacy of elacestrant for patients with metastatic ER-postiive, HER2-negative breast cancer.

Mariana Chavez-MacGregor, MD, shares results from the phase 3 SWOG S1207 trial, evaluating the addition of everolimus to standard endocrine therapy for patients with hormone receptor-positive, human epidermal growth factor 2-negative breast...

At the 2022 San Antonio Breast Cancer Symposium, Leif Ellisen, MD, PhD, presented an educational session on mechanisms of resistance to antibody drug conjugates.

Sara Tolaney, MD, MPH, discusses strategies for selecting patients with HER2 low breast cancer for treatment with trastuzumab deruxtecan.

Sara Hurvitz, MD, presents updated results from the phase 3 Destiny-Breast03 trial, comparing trastuzumab deruxtecan with trastuzumab emtansine in patients with HER2-positive metastatic breast cancer who progressed on first-line treatment.

At the 2022 San Antonio Breast Cancer Symposium, Sara Tolaney, MD, MPH, makes the case that HER2 low should not be considered a new breast cancer subtype.

Javid Moslehi, MD, discusses the cardiovascular risks associated with utilization of BTK inhibitors for patients with CLL and outlines best practices for managing these adverse events.